Our results revealed that TP53 was upregulated only in PL-treated MCF7 cells and PSS-treated T47D cells; however, MDM2 was downregulated in the four tested BC cell lines following exposure to PSS and PL (Fig. 7E). This evidence concerns the gene TP53 and breast cancer.